semaglutide heart disease STEP-HFpEF Trial Semaglutide reduces heart failure risk
Description
50 frames per movie
Of these patients, a large proportion initiating oral semaglutide (36.1%) had no prior evidence of GLP-1-therapy use, suggesting that early adoption included a substantial proportion of patients new to using GLP-1 medications
Semaglutide works mainly in the gut, pancreas, and brain areas that control appetite and blood sugar
they decrease weight and glucose levels, improve the lipid profile, and reduce the risk of major adverse cardiac events (36)
Globus sensation is fairly common
